Literature DB >> 17893461

Kvbeta1.3 reduces the degree of stereoselective bupivacaine block of Kv1.5 channels.

Cristina Arias1, Miriam Guizy, Miren David, Stefanie Marzian, Teresa González, Niels Decher, Carmen Valenzuela.   

Abstract

BACKGROUND: Kvbeta1.3 subunit modifies the gating and the pharmacology of Kv1.5 channels, decreasing their sensitivity to block induced by drugs, suggesting that Kvbeta1.3 competes with them for a binding site at Kv1.5 channels.
METHODS: Currents generated by the activation of Kv1.5 and Kv1.5 + Kvbeta1.3 channels expressed in HEK293 cells and Xenopus oocytes were recorded by using whole cell patch clamp and voltage clamp techniques.
RESULTS: Block of Kv1.5, but not that produced on Kv1.5 + Kvbeta1.3 channels, was voltage dependent. In both channels, bupivacaine block was time dependent. R(+)- and S(-)-bupivacaine blocked Kv1.5 with IC50 4.4 +/- 0.5 microM (n = 15) and 39.8 +/- 8.2 microM (n = 16; P < 0.05), respectively. These values increased fourfold for R(+)-bupivacaine (17.2 +/- 2.2 microM) and twofold for S(-)-bupivacaine (71.9 +/- 11.5 microM) in Kv1.5 + Kvbeta1.3 channels. Therefore, the degree of stereoselectivity (theta) decreased from 9 to 4 in the presence of Kvbeta1.3. The decrease in potency to block Kv1.5 + Kvbeta1.3 channels was the result of a less stable interaction between bupivacaine enantiomers and channels. Differences in stereoselectivity in each situation were due to a more favorable interaction between the channel and R(+)-bupivacaine. In the presence of Kvbeta1.3, stereoselectivity was abolished for V514A mutant channels (involved in bupivacaine binding but not in Kvbeta1.3 binding) but not for L510A (part of Kvbeta1.3 binding site).
CONCLUSIONS: The degree of stereoselective block of Kv1.5 decreases from 9 to 4 when Kvbeta1.3 is present. L510 is determinant for the modulation of bupivacaine block, because it is the only residue of the S6 segment that binds to both bupivacaine and Kvbeta1.3. These findings support an overlapping binding site for drugs and Kvbeta1.3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893461     DOI: 10.1097/01.anes.0000282100.32923.5c

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

1.  Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1.

Authors:  Tao Yang; Brian F McBride; Brenda F Leake; Richard B Kim; Dan M Roden
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Putative binding sites for arachidonic acid on the human cardiac Kv 1.5 channel.

Authors:  Jia-Yu Bai; Wei-Guang Ding; Akiko Kojima; Tomoyoshi Seto; Hiroshi Matsuura
Journal:  Br J Pharmacol       Date:  2015-10-22       Impact factor: 8.739

3.  Regulation of human cardiac Kv1.5 channels by extracellular acidification.

Authors:  Shuang Wang; Wei-Guang Ding; Jia-Yu Bai; Futoshi Toyoda; Min-Jie Wei; Hiroshi Matsuura
Journal:  Pflugers Arch       Date:  2016-10-28       Impact factor: 3.657

4.  Protein kinase C (PKC) activity regulates functional effects of Kvβ1.3 subunit on KV1.5 channels: identification of a cardiac Kv1.5 channelosome.

Authors:  Miren David; Álvaro Macías; Cristina Moreno; Ángela Prieto; Ramón Martínez-Mármol; Rubén Vicente; Teresa González; Antonio Felipe; Michael M Tamkun; Carmen Valenzuela
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

5.  Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.

Authors:  Oksana Sirenko; Evan F Cromwell; Carole Crittenden; Jessica A Wignall; Fred A Wright; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-01       Impact factor: 4.219

6.  Bupivacaine blocks N-type inactivating Kv channels in the open state: no allosteric effect on inactivation kinetics.

Authors:  Johanna Nilsson; Michael Madeja; Fredrik Elinder; Peter Arhem
Journal:  Biophys J       Date:  2008-09-12       Impact factor: 4.033

7.  PKC inhibition results in a Kv 1.5 + Kv β1.3 pharmacology closer to Kv 1.5 channels.

Authors:  A Macías; A de la Cruz; A Prieto; D A Peraza; M M Tamkun; T González; C Valenzuela
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

8.  Polyunsaturated Fatty acids modify the gating of kv channels.

Authors:  Cristina Moreno; Alvaro Macias; Angela Prieto; Alicia De La Cruz; Carmen Valenzuela
Journal:  Front Pharmacol       Date:  2012-09-10       Impact factor: 5.810

9.  Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells.

Authors:  José M Molina-Guijarro; Álvaro Macías; Carolina García; Eva Muñoz; Luis F García-Fernández; Miren David; Lucía Núñez; Juan F Martínez-Leal; Victoria Moneo; Carmen Cuevas; M Pilar Lillo; Carlos Villalobos Jorge; Carmen Valenzuela; Carlos M Galmarini
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

10.  Immunomodulation of voltage-dependent K+ channels in macrophages: molecular and biophysical consequences.

Authors:  Núria Villalonga; Miren David; Joanna Bielanska; Rubén Vicente; Núria Comes; Carmen Valenzuela; Antonio Felipe
Journal:  J Gen Physiol       Date:  2010-02       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.